Drug Development in NMIBC from Scientific, Regulatory, Clinician, and Patient Perspectives (2021)
3/4/21, 6:00 PM
America/New York GMT -4 summer
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?
Yair Lotan, John Sfakianos
Welcome, Opening Remarks, Bladder Cancer Advocacy Network (BCAN) Patient Panel, PANEL: Clinical Development of Therapies for NMIBC: What is Success?, Discussion, Q&A, SESSION ONE: Drug Development for BCG-Naïve NMIBC, Model Systems to Facilitate Development of Therapies for NMIBC, What Novel Therapies Can Compete (or Combine) with BCG in BCG-Naïve NMIBC?, Regulatory Considerations in the BCG-Naïve NMIBC Setting, Discussion, Q&A
Matthew Galsky, Yair Lotan, David McConkey, Aria F. Olumi, Carolyn J.M. Best, Seth Lerner, Noah Hahn, Brian Baumann, Elaine Chang, Phillip Abbosh, Robert Svatek, Chana Weinstock